ProCE Banner Activity

FLAURA2: Postprogression Outcomes of First-line Osimertinib ± Platinum-Based Chemotherapy in EGFR-Mutated Advanced NSCLC

Conference Coverage

Analysis of FLAURA2 showed that first-line treatment with osimertinib plus platinum-based chemotherapy prolonged time to both first and second subsequent treatment with a trend toward overall survival benefit compared with osimertinib alone in EGFR-mutated advanced NSCLC, as presented at the European Lung Cancer Congress 2024.

Released: May 03, 2024

Expiration: May 02, 2025


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc